JMP Securities initiated coverage of Elevation Oncology with an Outperform rating and $7 price target. The analyst says the company’s’ EO-3021 represents a new target for a well-established technology. The target Claudin 18.2 is substantially de-risked through naked antibodies, the analyst tells investors in a research note. JMP believes data on lead asset EO-3021 in the first half of 2024 in key indications with large unmet need will answer several key questions about the approach and should drive significant value.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELEV: